{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:03:35Z","timestamp":1700582615935},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,7,28]],"date-time":"2009-07-28T00:00:00Z","timestamp":1248739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00192-009-0957-z","type":"journal-article","created":{"date-parts":[[2009,7,27]],"date-time":"2009-07-27T10:03:10Z","timestamp":1248688990000},"page":"1285-1291","source":"Crossref","is-referenced-by-count":10,"title":["Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study"],"prefix":"10.1007","volume":"20","author":[{"given":"Daniel","family":"Altman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Granath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Mattiasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,28]]},"reference":[{"key":"957_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167\u2013178","journal-title":"Neurourol Urodyn"},{"key":"957_CR2","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306\u20131315","journal-title":"Eur Urol"},{"key":"957_CR3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","volume":"3","author":"KE Andersson","year":"2004","unstructured":"Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3:46\u201353","journal-title":"Lancet Neurol"},{"key":"957_CR4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","volume":"100","author":"P Abrams","year":"2007","unstructured":"Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987\u20131006","journal-title":"BJU Int"},{"key":"957_CR5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0024-3205(97)00057-X","volume":"60","author":"L Nilvebrant","year":"1997","unstructured":"Nilvebrant L, Hallen B, Larsson G (1997) Tolterodine\u2014a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 60:1129\u20131136","journal-title":"Life Sci"},{"key":"957_CR6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/PL00007103","volume":"19","author":"KE Andersson","year":"2001","unstructured":"Andersson KE, Chapple CR (2001) Oxybutynin and the overactive bladder. World J Urol 19:319\u2013323","journal-title":"World J Urol"},{"key":"957_CR7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1464-410X.2005.05745.x","volume":"96","author":"GG Kay","year":"2005","unstructured":"Kay GG, Wesnes KA (2005) Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 96:1055\u20131062","journal-title":"BJU Int"},{"key":"957_CR8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000127840","volume":"82","author":"K Masunaga","year":"2008","unstructured":"Masunaga K, Yoshida M, Inadome A, Murakami S, Sugiyama Y, Satoji Y, Maeda Y, Ueda S (2008) Pharmacological effects of solifenacin on human isolated urinary bladder. Pharmacology 82:43\u201352","journal-title":"Pharmacology"},{"key":"957_CR9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/diacare.27.5.1218","volume":"27","author":"JA Cramer","year":"2004","unstructured":"Cramer JA (2004) A systematic review of adherence with medications for diabetes. Diabetes care 27:1218\u20131224","journal-title":"Diabetes care"},{"key":"957_CR10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/pds.1433","volume":"16","author":"K Krigsman","year":"2007","unstructured":"Krigsman K, Nilsson JL, Ring L (2007) Adherence to multiple drug therapies: refill adherence to concomitant use of diabetes and asthma\/COPD medication. Pharmacoepidemiol Drug Saf 16:1120\u20131128","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"957_CR11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","volume":"104","author":"CJ Kelleher","year":"1997","unstructured":"Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988\u2013993","journal-title":"Br J Obstet Gynaecol"},{"key":"957_CR12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.eururo.2008.01.027","volume":"53","author":"DE Irwin","year":"2008","unstructured":"Irwin DE, Milsom I, Kopp Z, Abrams P (2008) Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 53:1029\u20131037","journal-title":"Eur Urol"},{"key":"957_CR13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1464-410X.2004.05022.x","volume":"94","author":"CR Chapple","year":"2004","unstructured":"Chapple CR (2004) Pharmacological therapy of benign prostatic hyperplasia\/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 94:738\u2013744","journal-title":"BJU Int"},{"key":"957_CR14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ucl.2006.06.005","volume":"33","author":"GW Davila","year":"2006","unstructured":"Davila GW, Starkman JS, Dmochowski RR (2006) Transdermal oxybutynin for overactive bladder. Urol Clin North Am 33:455\u2013463","journal-title":"Urol Clin North Am"},{"key":"957_CR15","doi-asserted-by":"crossref","unstructured":"Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev (3):CD003781.","DOI":"10.1002\/14651858.CD003781.pub2"},{"key":"957_CR16","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/nau.20500","volume":"26","author":"KE Andersson","year":"2007","unstructured":"Andersson KE (2007) LUTS treatment: future treatment options. Neurourol Urodyn 26:934\u2013947","journal-title":"Neurourol Urodyn"},{"key":"957_CR17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clinthera.2005.01.006","volume":"27","author":"GG Kay","year":"2005","unstructured":"Kay GG, Granville LJ (2005) Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 27:127\u2013138","journal-title":"Clin Ther"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-009-0957-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00192-009-0957-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-009-0957-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:50:56Z","timestamp":1558608656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00192-009-0957-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,28]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1007\/s00192-009-0957-z","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,28]]}}}